Your browser is no longer supported. Please, upgrade your browser.
Omeros Corporation
Index- P/E- EPS (ttm)-2.41 Insider Own3.80% Shs Outstand61.66M Perf Week0.77%
Market Cap1.14B Forward P/E- EPS next Y-1.12 Insider Trans-4.34% Shs Float58.93M Perf Month-7.64%
Income-138.10M PEG- EPS next Q-0.52 Inst Own56.10% Short Float22.23% Perf Quarter2.11%
Sales73.80M P/S15.45 EPS this Y-41.50% Inst Trans-1.72% Short Ratio17.77 Perf Half Y70.72%
Book/sh-1.96 P/B- EPS next Y36.70% ROA-92.50% Target Price27.33 Perf Year30.38%
Cash/sh2.17 P/C8.45 EPS next 5Y- ROE110.20% 52W Range9.25 - 25.46 Perf YTD28.60%
Dividend- P/FCF- EPS past 5Y-3.80% ROI-95.50% 52W High-28.00% Beta1.15
Dividend %- Quick Ratio4.10 Sales past 5Y40.40% Gross Margin98.80% 52W Low98.16% ATR0.88
Employees277 Current Ratio4.10 Sales Q/Q-68.30% Oper. Margin- RSI (14)48.38 Volatility5.49% 4.78%
OptionableYes Debt/Eq- EPS Q/Q-4.70% Profit Margin- Rel Volume0.40 Prev Close18.37
ShortableYes LT Debt/Eq- EarningsMar 01 AMC Payout- Avg Volume737.15K Price18.33
Recom2.10 SMA20-0.45% SMA50-6.98% SMA20022.65% Volume191,099 Change-0.22%
Feb-01-21Initiated UBS Buy $25
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
Aug-14-20Reiterated Maxim Group Buy $25 → $20
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Mar-23-21 08:45AM  
Mar-01-21 05:25PM  
Feb-25-21 09:37AM  
Feb-03-21 05:30AM  
Jan-26-21 08:45AM  
Jan-19-21 08:30AM  
Jan-11-21 04:30PM  
Dec-15-20 11:42PM  
Dec-05-20 02:43AM  
Dec-03-20 07:30AM  
Dec-02-20 08:57AM  
Nov-18-20 09:00AM  
Nov-12-20 09:54AM  
Nov-09-20 05:45PM  
Nov-05-20 07:00AM  
Nov-03-20 12:31PM  
Oct-28-20 09:00AM  
Oct-22-20 08:00AM  
Oct-20-20 09:56AM  
Oct-16-20 08:30AM  
Oct-15-20 08:00AM  
Oct-01-20 09:00AM  
Sep-14-20 02:10PM  
Sep-11-20 07:00AM  
Sep-09-20 08:45AM  
Sep-03-20 09:38AM  
Aug-31-20 08:18AM  
Aug-12-20 12:35PM  
Aug-11-20 08:20AM  
Aug-10-20 05:45PM  
Aug-06-20 12:30PM  
Jul-26-20 06:27AM  
Jul-15-20 03:06PM  
Jun-24-20 04:27PM  
Jun-12-20 08:30AM  
Jun-11-20 08:45AM  
Jun-08-20 02:28PM  
May-26-20 06:45PM  
May-14-20 09:00AM  
May-12-20 06:01AM  
May-11-20 06:55PM  
May-08-20 08:36AM  
May-05-20 07:00AM  
Mar-11-20 03:38PM  
Mar-04-20 10:00AM  
Mar-02-20 05:35PM  
Feb-24-20 07:00AM  
Feb-11-20 09:35AM  
Feb-03-20 03:49PM  
Jan-23-20 05:30PM  
Dec-20-19 05:16PM  
Dec-18-19 08:30AM  
Dec-16-19 08:30AM  
Dec-13-19 09:30AM  
Dec-10-19 08:30AM  
Dec-05-19 07:14AM  
Dec-04-19 04:11PM  
Dec-03-19 11:45PM  
Nov-20-19 08:45AM  
Nov-19-19 08:45AM  
Nov-16-19 08:10AM  
Nov-13-19 02:00PM  
Nov-12-19 05:35PM  
Nov-11-19 05:16PM  
Nov-08-19 08:30AM  
Nov-07-19 05:45PM  
Nov-06-19 08:15AM  
Nov-04-19 03:00PM  
Nov-01-19 11:22AM  
Oct-29-19 09:00AM  
Oct-28-19 08:45AM  
Oct-21-19 09:46AM  
Oct-18-19 04:31AM  
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 08Option Exercise4.1035,206144,3452,062,192Apr 08 07:52 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 08Sale17.7635,206625,2592,026,986Apr 08 07:52 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 07Option Exercise4.1037,407153,3692,064,393Apr 08 07:52 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 07Sale17.9137,407669,9592,026,986Apr 08 07:52 PM
Demopulos Peter A MDDirectorFeb 22Option Exercise4.9210,00049,150198,516Feb 23 06:43 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 22Option Exercise10.278,10083,18722,100Feb 23 05:20 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 22Sale23.288,100188,56814,000Feb 23 05:20 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 19Option Exercise10.2710,000102,70024,000Feb 23 05:20 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 19Sale22.6410,000226,40014,000Feb 23 05:20 PM
Hood Leroy E. MD PhDDirectorFeb 12Option Exercise4.535,00022,65074,390Feb 17 05:15 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 10Option Exercise10.271,90019,51315,900Feb 12 05:05 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 10Sale22.491,90042,73114,000Feb 12 05:05 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOJan 20Option Exercise9.3710,00093,70014,000Jan 21 05:15 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOJan 19Sale19.959,500189,5254,000Jan 21 05:15 PM
Cable Thomas J.DirectorJan 13Option Exercise4.535,00022,65040,067Jan 15 05:15 PM
Cable Thomas J.DirectorJan 13Sale16.975,00084,85035,067Jan 15 05:15 PM
Cable Thomas J.DirectorMay 13Option Exercise5.925,00029,60040,067May 15 08:00 PM
Cable Thomas J.DirectorMay 13Sale14.405,00071,99835,067May 15 08:00 PM